Japan-News

Bringing Immuno-Oncology into Focus

New Biomark assay enables efficient interrogation of the tumor microenvironment

特集

Biomark HD overview

The flexible Biomark system provides scalable performance to meet the complex needs of the molecular research laboratory. Achieve new economies of scale across multiple applications, all on the same system:

  • qPCR for gene and miRNA expression
  • Genotyping
  • Copy number variation
  • Digital PCR
Learn More

Tumor gene expression has proven effective in measuring immune response during cancer progression and therapeutic response. As emerging therapies reveal new biomarkers and expand the need for samples, the costs and labor required to complete this important work also rise. Cancer researchers now have a reliable, sensitive and cost-effective tool for identifying gene expression signatures from immune and cancer cells: the new Advanta™ Immuno-Oncology Gene Expression Assay, used with the Biomark™ HD system.

A powerful immuno-oncology focused assay

The Advanta Immuno-Oncology Gene Expression Assay was developed in collaboration with leading academic and biopharma researchers to provide the right balance of biomarker breadth, assay flexibility and workflow efficiency.

The panel consists of 170 genes, including 91 reported in Nature, where Roy Herbst et al. defined a gene set representing tumor and immune response. The panel includes markers for:

  • Immune cell identification
  • Immune and cancer cell function
  • Immune regulation and cell fate
  • Checkpoint therapy response

Optimized for FFPE and fresh frozen tumor samples, the Advanta Immuno-Oncology Gene Expression Assay uses TaqMan® chemistry to sensitively measure gene expression, with five reference genes serving as analysis controls. Combined with Fluidigm microfluidics technology, the assay uniquely offers significant workflow efficiencies over traditional gene expression profiling methods. Each reaction is miniaturized to nanoliter volume and controlled using precise automation to empower accurate and cost-effective qPCR analysis across a large dynamic range. Since assay introduction into the integrated fluidic circuit (IFC) is under user control, researchers also have the flexibility to add up to 17 new assays or exchange gene assays within the panel to achieve experimental goals—all without affecting the original panel content, protocol or workflow.

Immuno-Oncology Expression Assay

Panel A   Panel B
ARG1 CLEC4C IL12A PDCD1LG2 (PD-L2)   APOBEC3A CXCR4 IFNA2 NKG7
BTLA CSF2 IL13 PRF1   APOBEC3B CYBB IGHA1 NRAS
CCL2 CTLA4 IL17A PTGER2   ARG2 DGAT2 IGHG1 NT5E
CCL22 CX3CL1 IL17F PTGER4   CA4 EBI3 IGHM PYGL
CCL28 CXCL10 IL1B PTGS2   CCL18 ERBB2 JCHAIN (IGJ) SLAMF7
CCR5 CXCL8 IL2 PTPRC   CCL21 FASLG IGKC SLAMF8
CCR7 CXCL9 IL2RA RORC   CCL3 FCER1G IGLJ3 STAT1
CD1C CXCR3 IL4 SDHA   CCL4 FCRLA IGSF6 STAT2
CD244 EOMES IL6 SP2   CCL5 FYB IL10RA STAT3
CD27 EPCAM IL7 TBX21   CD160 GATA3 IL12B STAT5A
CD274 (PD-L1) FOXP3 IL7R TGFB1   CD19 GNLY IL15 STAT5B
CD276 GZMA ITGAM TMEM55B   CD1D GZMH IL2RG STAT6
CD28 GZMB ITGAX TNF   CD2 GZMK IRF9 TLR7
CD3E HAVCR2 ITGB2 TNFRSF14   CD22 HLA-DMB ISG15 TLR8
CD4 HLA-A KLRK1 TNFRSF4   CD37 HLA-DPB1 JAK2 TNFAIP8
CD40 HLA-B LAG3 TNFRSF9   CD52 HLA-DQB1 KREMEN1 TNFRSF18
CD40LG HLA-C LGALS9 TNFSF4   CD53 HLA-DRB1 LAPTM5 TNFSF18
CD48 HMOX1 MAP4K1 TNFSF9   CD63 IFI27 LCK  
CD69 ICAM1 MICA VCAM1   CTSS IFIT2 LRG1  
CD70 ICOS MICB VEGFA          
CD80 IDO1 MS4A1 VPS33B          
CD86 IFNG NCAM1 VTCN1          
CD8A IL10 PDCD1 (PD-1)     Housekeeping genes for panels A and B:
B2M, ACTB, GUSB, TFRC

Table 1. The Advanta Immuno-Oncology Gene Expression Assay panels A and B. This two-panel set includes 91 target genes and 5 housekeeping genes on Panel A and 74 target genes and the same 5 housekeeping genes on Panel B. Panel B reserves 17 open assay inlets, so you have the added flexiblity to add new assays over time for customization. Each panel is available in packs of 2 or 10 (192 or 960 samples, respectively)

Sample case study

In a 2016 paper published by The Lancet for the POPLAR study, “Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer,” Louis Fehrenbacher et al. detailed how they “assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analyzed by PD-L1 expression levels on tumor cells and tumor-infiltrating immune cells and in the intention-to-treat population.” The team showed that “patients with pre-existing immunity, defined by high T-effector–interferon-γ-associated gene expression, had improved overall survival with atezolizumab.”

Fehrenbacher’s group noted that atezolizumab “significantly improved survival compared with docetaxel in patients with previously treated NSCLC. Improvement correlated with PD-L1 immunohistochemistry expression on tumor ce/p>lls and tumor-infiltrating immune cells,” leading them to conclude: “PD-L1 expression is predictive for atezolizumab benefit. Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy.”

The researchers performed the clinical trial using immunohistochemistry, and also ran a gene expression panel of 91 genes featured in the Herbst paper. These genes are included in the Advanta Immuno-Oncology Gene Expression Assay. The team subsequently used these results to develop a gene signature based on a subset of the panel, effectively predicting therapeutic response that provides data that could potentially be used for developing future diagnostics tests.

Achieve greater overall productivity

The Advanta Immuno-Oncology Gene Expression Assay is optimized to run on the industry-proven Biomark HD system. This automated system enables researchers to easily run up to 96 samples at once with limited hands-on time, while delivering trusted performance. Together with the capability to sensitively detect biomarkers across defined T cell subsets, immune regulation, immune cell fate, cytokines, chemokines and more with exceptional cost-efficiency, this new assay offers an ideal solution to meet the rigorous demands of translational research studies.

Advanta IO Gene Expression Assay ordering information

Product Name Contents Part Number
Advanta Immuno-Oncology Gene Expression Assay Panel A-2 IFCs Reagents, assay, syringes, IFCs 101-6082
Advanta Immuno-Oncology Gene Expression Assay Panel B-2 IFCs Reagents, assay, syringes, IFCs 101-6083
Advanta Immuno-Oncology Gene Expression Assay Panel A & B-4 IFCs Reagents, assay, syringes, IFCs 101-6084

Contact us to learn more about the Biomark HD system and the Advanta Immuno-Oncology Gene Expression Assay.

fluidigm

For Research Use Only. Not for use in diagnostic procedures.